In a statement, Novo Nordisk said the rapprochement between the two companies is "a meaningful win for patients in the US" and will expand access to Ozempic and Wegovy, adding that the two products have been "evaluated for safety and efficacy." The company also said that it "welcomes Hims & Hers shifting their GLP-1 business model to focus on increasing access to affordable, branded FDA-approved medicines." It has also agreed to drop its lawsuit with Hims & Hers that followed the compounded oral semaglutide announcement
It allows for careful control of loading and flow rates
Eur J Biochem (1994) 225:11516
Now, there are deadlines for pharmacies and outsourcing facilities in April and May, respectively, to cease production, while the provided off-ramp gives patients and providers time for medication transition
As displayed on the company website on December 26, 2025, multi-pack pricing ranged from $27.99$44.99 per pack depending on quantity, drawing interest from those seeking non-prescription alternatives
same active ingredients, different formulations and packaging All injectable GLP-1 medications are biologics large-molecule proteins that are more sensitive to temperature, light, and physical degradation than small-molecule oral medications
